RE:RE:TBP MASSIVE NEWSWIRE POSITIVE APPLICATION IN COVID-19~Sorry SamV21,
please read the WHOLE story.
Tetra explains why we shareholders needed to wait until NOW for approval. Short answer, ARDS-003 is a new drug. OTTAWA, ON / ACCESSWIRE / March 30, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is excited to announce that Health Canada supports the filing of a Clinical Trial Application for assessing their novel drug candidate, ARDS-003, in patients with COVID-19.
ARDS-003 is a new patent protected therapeutic developed to treat hyperinflammatory conditions, such as those seen in patients suffering from COVID-19 viral infections. Shareholders have been waiting for this moment since late autumn 2020. Health Canada, like other regulatory agencies, had to complete a full review of the animal toxicology and safety data to ensure that the new drug, ARDS-003, is safe for human use. This takes more time than assessing the potential safety of an existing, repurposed drug.
Tetra's trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. Tetra will use this study to demonstrate that its ARDS-003 drug can help prevent the acute respiratory distress seen in serious complications of COVID-19.